title: Evidence for a nucleus accumbens CCK2 receptor regulation of rat ventral pallidal GABA levels: a dual probe microdialysis study.
abstract: We employed dual probe microdialysis in the nucleus accumbens and ipsilateral ventral pallidum of the halothane anaesthetized rat to investigate the effect of intra-accumbens perfusion with the sulphated octapeptide cholecystokinin (CCK-8S, 10-1000 nM, 60 min) alone and in the presence of the selective CCK1 and CCK2 receptor antagonists L-364,718 (10 and 100 nM) and PD134308 (10 nM), tetrodotoxin (TTX, 1000 nM) and the GABA(A) receptor antagonist bicuculline (1000 nM), on dialysate GABA levels in the ventral pallidum. Intra-accumbens perfusion with the 100 and 1000 nM concentration of CCK-8S was associated with a significant decrease (-16+/-3% and -23+/-3% vs basal, respectively) in ventral pallidum GABA levels. The CCK-8S (1000 nM) induced decrease in ventral pallidal dialysate GABA levels was abolished when PD134308, TTX and bicuculline, but not L-364,718, were included into the perfusion medium of the accumbens probe. The data indicate that nucleus accumbens CCK-8S exerts a CCK2 receptor mediated inhibition of ventral pallidal GABA levels. Furthermore, the TTX and bicuculline sensitivity of this effect suggests that this is possibly mediated via CCK2 receptors probably located on local GABA interneurons.
authors.affiliation: Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Ferrara, Italy. frl@ifeuniv.unife.it
authors.forename: L
authors.initials: L
authors.lastname: Ferraro
authors.forename: W T
authors.initials: WT
authors.lastname: O'Connor
authors.forename: J
authors.initials: J
authors.lastname: Glennon
authors.forename: M C
authors.initials: MC
authors.lastname: Tomasini
authors.forename: B W
authors.initials: BW
authors.lastname: Bebe
authors.forename: S
authors.initials: S
authors.lastname: Tanganelli
authors.forename: T
authors.initials: T
authors.lastname: Antonelli
mesh_terms: D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D020109:Devazepide / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives* / Q000494:pharmacology; D017551:Microdialysis / Q000379:methods; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D012844:Sincalide / Q000031:analogs & derivatives* / Q000494:pharmacology*; D013779:Tetrodotoxin / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: C090019:8-sulfocholecystokinin octapeptide; D006727:Hormone Antagonists; D007211:Indoles; D011949:Receptors, Cholecystokinin; C065599:PD 134308; D013779:Tetrodotoxin; D005680:gamma-Aminobutyric Acid; D008536:Meglumine; D020109:Devazepide; D012844:Sincalide; D001640:Bicuculline